Treatment of Oral Cryptococcus Lesions
For oral cryptococcal lesions, treat with fluconazole 400 mg daily for 6-12 months if the lesions are isolated and mild-to-moderate without evidence of CNS or disseminated disease 1.
Critical First Step: Rule Out Dissemination
Before initiating treatment for what appears to be isolated oral cryptococcosis, you must:
- Perform lumbar puncture to exclude CNS involvement, as this fundamentally changes management 1
- Obtain blood cultures and serum cryptococcal antigen testing
- Consider chest imaging to evaluate for pulmonary involvement
- If any evidence of dissemination or CNS disease exists, treat as cryptococcal meningoencephalitis (see below)
Treatment Algorithm Based on Disease Extent
Isolated Oral Lesions (Non-CNS, Single Site)
If CNS disease is ruled out, fungemia is absent, and infection is at a single site:
- Fluconazole 400 mg (6 mg/kg) daily orally for 6-12 months 1
- This applies to both immunosuppressed and non-immunosuppressed patients with localized disease
Disseminated Disease or CNS Involvement
If oral lesions are part of disseminated cryptococcosis (≥2 noncontiguous sites) or CNS disease is present, treat as cryptococcal meningoencephalitis:
Induction therapy:
- Amphotericin B deoxycholate 0.7-1.0 mg/kg/day IV PLUS flucytosine 100 mg/kg/day orally (divided into 4 doses) for at least 2 weeks 1
- Alternative: Liposomal amphotericin B 3-4 mg/kg/day IV if renal dysfunction is present or anticipated 1
Consolidation therapy:
- Fluconazole 400 mg daily orally for minimum 8 weeks 1
Maintenance therapy:
- Fluconazole 200 mg daily for 6-12 months (longer in immunosuppressed patients) 1
Special Populations
Transplant Recipients
For oral lesions in transplant recipients with mild-to-moderate non-CNS disease:
- Fluconazole 400 mg (6 mg/kg) daily for 6-12 months 1
- Consider stepwise reduction of immunosuppression, starting with corticosteroids 1
HIV-Infected Patients
- Initiate HAART 2-10 weeks after starting antifungal therapy 1
- Can discontinue maintenance therapy if CD4 >100 cells/μL and undetectable viral load for ≥3 months after minimum 12 months of treatment 1
Common Pitfalls to Avoid
Never assume oral lesions are isolated - Cryptococcus has high propensity for CNS involvement, which is life-threatening if missed. Always perform LP unless contraindicated 1
Don't use inadequate fluconazole dosing - 400 mg daily is the minimum; lower doses risk treatment failure 1
Avoid premature discontinuation - Complete the full 6-12 month course even if lesions resolve clinically, as relapse rates are high with shorter courses 1
Monitor for immune reconstitution inflammatory syndrome (IRIS) in HIV patients starting HAART - may see paradoxical worsening of oral lesions despite appropriate antifungal therapy 1
Clinical Context from Recent Literature
A 2024 systematic review of oral cryptococcosis found that amphotericin B was the primary therapy in most reported cases, with 65% survival rate 2. The palate and tongue are most commonly affected sites 2. However, these case reports often describe disseminated disease rather than truly isolated oral lesions, reinforcing the importance of thorough evaluation for systemic involvement.
The key determinant is whether disease is localized or disseminated - this single factor determines whether you use oral fluconazole monotherapy versus aggressive induction with amphotericin B plus flucytosine.